Drug Profile
Vincristine liposomal - Acrotech Biopharma
Alternative Names: Marqibo; Sphingosomal vincristine; Vincacine; Vincristine sulfate injection; Vincristine sulfate liposomes injection; VSLILatest Information Update: 10 Mar 2023
Price :
$50
*
At a glance
- Originator Inex Pharmaceuticals Corporation
- Developer Acrotech Biopharma; CASI Pharmaceuticals; Hana Biosciences; Inex Pharmaceuticals Corporation; Talon Therapeutics; University of Texas M. D. Anderson Cancer Center
- Class Antineoplastics; Vinca alkaloids
- Mechanism of Action Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Marketed Precursor cell lymphoblastic leukaemia-lymphoma
- Phase III Non-Hodgkin's lymphoma
- Phase I/II Cancer
- Discontinued Colorectal cancer; Malignant melanoma; Multiple myeloma; Pancreatic cancer; Small cell lung cancer
Most Recent Events
- 10 Mar 2023 Discontinued - Preclinical for Multiple myeloma in USA (IV)
- 12 May 2022 Spectrum Pharmaceuticals completes a phase I trial for Non-Hodgkin's lymphoma (Combination therapy, Second-line therapy or greater) in USA (IV) (NCT02257242)
- 05 Dec 2020 Efficacy and safety data from a phase I trial in indolent Non-Hodgkin's lymphoma presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology (ASH-2020)